10 results about "Cyclo-oxygenase" patented technology

To provide an andrographis paniculata diterpene lactone compound as well as extraction method and application thereof.SOLUTION: The andrographis paniculata diterpene lactone compound provided by the invention has a structure as shown in any one of formulas 1-7 and is novel in structure. The andrographis paniculata diterpene lactone compound extracted and separated from andrographis paniculata has a good anti-inflammatory effect, and has a good down-regulation effect on secretion of NO, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in a lipopolysaccharide (LPS) induced mouse mononuclear macrophage (RAW264.7 cell) inflammation model; the compound also has a good inhibition effect on expression of inducible nitric oxide synthase (INOS) and cyclooxygenase-2 (COX-2) proteins, and can be applied to preparation of anti-inflammatory drugs.SELECTED DRAWING: Figure 1

The present disclosure relates to methods of diseases and / or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.

The application discloses a preparation method of copper-azo salicylic acid nanosheet for cyclooxygenase-2 inhibition, which comprises the following steps: (1) dissolving copper nitrate trihydrate and azo salicylic acid in an N,N-dimethylformamide solution of ethanol, performing ultrasonic dissolution, and then performing hydrothermal reaction, cooling to room temperature after reaction, and centrifuging the reaction solution to collect the solid; (2) dispersing the solid in water again, obtaining uniform two-dimensional nanosheet after ultrasonic centrifugation, and washing and vacuum drying the nanosheet to obtain the product. The nanosheet is prepared by coordinating the multidentate ligand formed by 5-aminosalicylic acid through an azo bond and Cu 2+ The nanosheet avoids the toxic side effects brought by directly taking COX-2 inhibitors, and can efficiently deliver 5-aminosalicylic acid to a tumor site through enhanced permeability and retention effect, so as to be beneficial to inhibiting the expression of COX-2 / PGE2, and the released Cu 2+ Also can catalyze Fenton-like reaction to produce hydroxyl radicals to kill tumor cells.

The present invention relates to the field of pharmaceutical applications, and in particular to a marker for viral pneumonia and its application, wherein the marker for viral pneumonia is prostaglandin E2 and / or prostaglandin M. The present invention uses prostaglandin E2 and / or prostaglandin M as markers for viral pneumonia, and the use of cyclooxygenase II inhibitors can effectively and quickly reduce prostaglandins, reverse the progression of common and severe cases, block the occurrence of critical illness, promote viral conversion to negative, pneumonia absorption and health recovery. The drug will expand its clinical use scope upon further confirmation of its efficacy, incorporate the treatment method into clinical diagnosis and treatment plans, and provide new strategies and diagnosis and treatment methods for the comprehensive treatment of new coronary pneumonia.

The present invention discloses a class of divalent platinum complexes containing non-steroidal anti-inflammatory drug structural units, their derivatives, preparation methods, pharmaceutical compositions and applications. The structure of this class of divalent platinum complexes is as follows: The derivatives of this class of divalent platinum complexes refer to isomers of the said divalent platinum complexes or mixtures thereof. When this class of divalent platinum complexes and their derivatives act on cancer cells, they can cause apoptosis by inducing DNA damage and the production of reactive oxygen species, and can also effectively inhibit the growth of cancer cells by down-regulating the expression of cyclooxygenase 2 to reduce inflammation. At the same time, this class of divalent platinum complexes with C=N double bonds can also target tumors using the acidic microenvironment of tumors, reduce tissue toxicity, show the characteristics of high efficiency and low toxicity in anti-tumor, and can overcome cisplatin resistance to a certain extent, and can be prepared into anti-tumor drugs. In addition, the synthesis method of this class of divalent platinum complexes is simple and easy to operate.

The application provides a whey protein hydrolysate and application thereof in preparation of anti-inflammatory, antioxidant or allergy relief related products. The preparation method has the advantages of high preparation efficiency, fast speed and sufficient hydrolysis. The whey protein hydrolysate obtained through the preparation method is of excellent quality, rich in nutrition, easy to be absorbed by the human body, and can improve the cyclooxygenase-2 inhibition rate, improve the free radical clearance rate, and relieve the kidney and liver damage caused by the body allergy, and thus has the effects of anti-inflammation, anti-oxidation and allergy relief.

This invention discloses a 7-O-7' lignan (+) / (–)-7- epi -oryzativol, its preparation method, and its applications belong to the field of pharmaceutical chemistry technology. The 7-O-7' lignan (+) / (–)-7- epi -oryzativol has the structure shown in formula C. This class of compounds was first obtained from Artemisia bulbifera (… Laportea bulbifera The compound was isolated from (+) / (–)-7- epi -oryzativol exhibits significant inhibitory activity against cyclooxygenase-2 (COX-2), and compound (+)-7- epi -oryzativol has a high COX-2 selectivity index and exhibits significant anti-inflammatory effects, making it suitable for use in the preparation of anti-inflammatory drugs.

The invention discloses a monofluoromethyl etoricoxib, the structure of which is shown below: the active group of the monofluoromethyl etoricoxib of the invention is similar to that of etoricoxib, and the fluorine atom changes the spatiality, electronegativity, biological properties, etc. of the molecule, thereby maintaining or increasing its inhibition and selectivity to cyclooxygenase COX-2 to a certain extent, and can be used as a potential anti-inflammatory and analgesic drug, and has wide application value and market value.

This invention relates to a novel application of all-trans retinoic acid combined with a cyclooxygenase inhibitor in the treatment of prostate cancer. The all-trans retinoic acid is used to regulate gene expression and metabolic processes in tumor cells, promoting cell differentiation and tumor suppressor signaling pathways. The cyclooxygenase inhibitor is used to inhibit prostaglandin production induced by all-trans retinoic acid treatment. The cyclooxygenase inhibitor includes small molecule compounds that specifically inhibit / antagonize cyclooxygenase, interfering molecules that specifically interfere with cyclooxygenase gene expression, gene-editing reagents that specifically knock out the cyclooxygenase gene, reagents that downregulate / lose the function of cyclooxygenase, or antibodies that specifically bind to cyclooxygenase. The advantages are: it reveals that the combination of all-trans retinoic acid and a cyclooxygenase inhibitor reduces the immunosuppressive microenvironment in the tumor during prostate cancer treatment, thereby enhancing the tumor-suppressive effect and strengthening anti-tumor immunity.

The invention provides an application of celecoxib in preparation of a medicament for treating olfactory disorder, relates to the technical field of biomedicine, and is technically characterized in that the application of celecoxib in preparation of a medicament for treating olfactory disorder is provided, a non-steroidal anti-inflammatory medicament, namely celecoxib, is a selective inhibitor of epoxidase-2, and can be used for preparing a medicament for treating olfactory disorder. The traditional Chinese medicine composition is mainly used for treating osteoarthritis and rheumatoid arthritis. The COX-2 is a rate-limiting enzyme for synthesizing prostaglandin, and the expression level of the COX-2 is up-regulated when an organism is subjected to harmful stimulation (such as inflammation, oxidative stress, autoimmune response, mechanical injury and the like) and is induced by a transforming growth factor TGF-beta. In addition to regulating inflammatory response, the compound also can participate in regulating cell growth, migration, proliferation, autophagy and apoptosis. An olfactory dysfunction model induced by methimazole (MMI) is established, and the potential treatment effect of the celecoxib on the olfactory dysfunction is provided on the basis of behavioral and histological experiments, so that the celecoxib can be proved to be capable of preparing the medicine for treating the olfactory dysfunction.